Gain Therapeutics (GANX) Competitors

Gain Therapeutics (NASDAQ:GANX) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, community ranking, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Do analysts rate GANX or URGN?

Gain Therapeutics presently has a consensus price target of $8.20, suggesting a potential upside of 355.56%. UroGen Pharma has a consensus price target of $23.14, suggesting a potential upside of 108.87%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Gain Therapeutics is more favorable than UroGen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
UroGen Pharma	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88

Which has stronger valuation and earnings, GANX or URGN?

Gain Therapeutics has higher earnings, but lower revenue than UroGen Pharma. UroGen Pharma is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,078.06	-$22.27M	-$0.86	-2.09
UroGen Pharma	$91.87M	5.56	-$102.24M	-$3.18	-3.48

Is GANX or URGN more profitable?

Gain Therapeutics has a net margin of 0.00% compared to UroGen Pharma's net margin of -129.11%. UroGen Pharma's return on equity of 0.00% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-203.91%	-128.05%
UroGen Pharma	-129.11%	N/A	-47.94%

Do insiders and institutionals have more ownership in GANX or URGN?

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of UroGen Pharma shares are owned by institutional investors. 7.2% of Gain Therapeutics shares are owned by company insiders. Comparatively, 5.1% of UroGen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor GANX or URGN?

UroGen Pharma received 343 more outperform votes than Gain Therapeutics when rated by MarketBeat users. Likewise, 74.32% of users gave UroGen Pharma an outperform vote while only 73.58% of users gave Gain Therapeutics an outperform vote.

Company	Underperform	Outperform
Gain Therapeutics	Outperform Votes 39 73.58%	Underperform Votes 14 26.42%
UroGen Pharma	Outperform Votes 382 74.32%	Underperform Votes 132 25.68%

Does the media favor GANX or URGN?

In the previous week, UroGen Pharma had 56 more articles in the media than Gain Therapeutics. MarketBeat recorded 58 mentions for UroGen Pharma and 2 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.96 beat UroGen Pharma's score of 0.07 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
UroGen Pharma	4 Very Positive mention(s)	7 Positive mention(s)	38 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility & risk, GANX or URGN?

Gain Therapeutics has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Summary

Gain Therapeutics beats UroGen Pharma on 9 of the 17 factors compared between the two stocks.